Skip to main content

Advertisement

Table 2 Patients’ clinical characteristics after treatment with cTACE and DEB-TACE. (N = 273)

From: Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Variables cTACE (n = 201) DEB-TACE (n = 72) p-value
GOT (IU/L) 156.76 ± 176.58 73.31 ± 45.50 < 0.001
GOT
 Not normal 153 (76.1) 46 (63.9) 0.045
 Normal 48 (23.9) 26 (36.1)  
GPT (IU/L) 170.91 ± 266.13 94.17 ± 101.44 0.014
GPT
 Not normal 139 (69.2) 47 (65.3) 0.545
 Normal 62 (30.8) 25 (34.7)  
Bilirubin (mg/dL) 1.38 ± 0.99 0.98 ± 0.57 0.002
Bilirubin
 Not normal 75 (37.3) 14 (19.4) 0.006
 Normal 126 (62.7) 58 (80.6)  
Albumin (g/dL) 3.81 ± 0.43 3.87 ± 0.42 0.325
Albumin
 Not normal 37 (18.4) 12 (16.7) 0.741
 Normal 164 (81.6) 60 (83.3)  
Cholangitis
 No 193 (96) 70 (97.2) 0.641
 Yes 8 (4) 2 (2.8)  
  1. Aspartate aminotransferase (GOT), Alanine aminotransferase (GPT)
  2. Data are summarized as mean ± SD and n (%) for continuous and categorical variables by treatment. Differences between treatments were compared using Mann-Whitney U test for continuous variables and Chi-square test / or Fisher’s exact test for categorical variables
  3. All serious AE were classified as cholangitis, none as biloma
  4. Bold p-values indicate statistical significance (p < 0.05)